KINIKSA target price at $27.81 +37.4%Kiniksa has activated a double bottom chart pattern that may lead the price to $27.81 that is +37.4% from current price.Longby compoundinterest7Updated 0
KNSA Ascending Triangle and PDUFAUpdated ascending trend line. General thesis still holding. Longby gruenbergerUpdated 1
KNSA Ascending Triangle and PDFUAHello, Please pardon my charting. I find it is best to combine TA and some DD for the best trades lately. Definitely a solid level of resistance and higher lows in the weeks leading up. Notes regarding the drug in question, Rilonacept, which addresses recurrent pericarditis. "In RHAPSODY, the primary efficacy endpoint of time-to-first adjudicated pericarditis recurrence in the randomized withdrawal period was highly statistically significant (Hazard Ratio = 0.04, p<0.0001). Additionally, annualized incidence of pericarditis recurrence decreased from 4.42 episodes per year prior to the study to 0.15 episodes per year while on rilonacept treatment. All major secondary endpoints were also highly statistically significant. Rilonacept was well-tolerated in the study, with adverse events consistent with the U.S. Food and Drug Administration (FDA)-approved label for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS). The most common adverse events were injection site reactions and upper respiratory tract infections. There were no drug-related serious adverse events." this looks good.Longby gruenbergerUpdated 1
Rising wedge rising wedge fda approval date is the 21st and has priority review i bought in and doubled my shares of dip today Shortby xxtamedtacoxx71
KNSA PDUFA PlayLooking to see if PDUFA pushes this past upper resistance levels. Monthly huge inverse head and shoulder pattern. This one is set to move higher.Longby shlobby2
KNSA Harmonics: 270% Gain in One to Two YearsFundamental and Technical Update coming soon! (Check Below for entry harmonic pattern.)Longby Antikythera_MechanismUpdated 0
Ride the MomentumAnnounced that six COVID-19 patients treated with mavrilimumab in Italy all responded to treatment, and 3 patients were discharged within 5 days. A follow-on controlled study in Italy is planned. Shares closed the week up 43% to $17.91. - BioPharmCatalyst Breaking through the recent top will be a strong indicator for further upside movement. Hovering aorund the recent top without a follow through could indicate not enough buying power and distribution is taking place and a strong move in the downside direction could occur. Take the potential support levels with a grain of salt as there is only 52.23M Shares Outstanding and a share float of 18.79M. Short Float is currently 7.19% Consensus Analyst Profit Target = 25.50$ according to MarketBeat Most recent: 4/1/2020 Bank of America 25$Longby Charlestrad3r4